# Best Peptides for Erectile Dysfunction: Clinical Evidence (2026)

> A clinical-editorial ranking of the peptides studied for erectile dysfunction — melanocortin agents (PT-141, melanotan-2) and kisspeptin — graded honestly against the AUA first-line standard. No peptide is FDA-approved for ED.

*Published 2026-07-01 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Erectile dysfunction is one of the few peptide areas with genuine human trial data — but it points away from most marketing. **No peptide is FDA-approved for ED.** Bremelanotide (PT-141) has the deepest human male-ED dataset yet was stopped for blood-pressure safety; melanotan-2 has a real 10-man erectogenic signal but has caused permanent, PDE5i-unresponsive ED via priapism; kisspeptin is a single small surrogate-endpoint RCT. For an actual patient in 2026, the evidence-based answer remains a cardiometabolic/hormonal workup plus first-line PDE5 inhibitors.[9](https://peptidevox.com/#r9)

The peptides relevant to erectile dysfunction are **centrally-acting melanocortin and reproductive-neuropeptide agents** that work on the brain's sexual-arousal circuitry — fundamentally differently from the first-line standard of care, the oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) that act peripherally on penile blood flow and are the AUA-recommended first-line therapy.[9](https://peptidevox.com/#r9) This monograph ranks those peptides by the strength of human ED evidence and grades each one honestly — the highest grade here is B.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol, and not a sourcing or buying guide. The peptides discussed are prescription-only, investigational, or unapproved drugs — not supplements. Erectile dysfunction is frequently the first visible sign of treatable cardiovascular, hormonal or metabolic disease and warrants a real medical workup, not self-injection of gray-market peptides. Consult a board-certified physician.*

## How can peptides affect erections at all?

A normal erection requires an intact central arousal signal, an intact nerve supply, healthy vascular inflow, and adequate smooth-muscle relaxation in the corpus cavernosum. PDE5 inhibitors act at the very last step — they block breakdown of cyclic GMP, prolonging nitric-oxide-driven smooth-muscle relaxation and penile blood flow.[9](https://peptidevox.com/#r9) They do nothing for desire and require the upstream arousal cascade to fire in the first place, which is why they fail in a meaningful subset of men — those with diabetic neuropathy, post-prostatectomy nerve injury, or low desire.

The peptides relevant to ED act **upstream, in the brain**, on the arousal signal itself. The melanocortin agents (PT-141 and its parent melanotan-2) are synthetic alpha-MSH analogues that agonize central melanocortin-3 and -4 receptors (MC3R/MC4R) in the hypothalamus, triggering a pro-erectile output that is independent of the peripheral nitric-oxide/PDE5 pathway.[2](https://peptidevox.com/#r2)[6](https://peptidevox.com/#r6) That is mechanistically appealing precisely because it could in principle help men who do not respond to PDE5 inhibitors — but the same receptor promiscuity that drives skin tanning and erections also drives nausea, flushing, and, critically, transient blood-pressure increases.[2](https://peptidevox.com/#r2) Kisspeptin, by contrast, is the master upstream regulator of reproductive hormones that also appears to act directly on limbic/sexual-processing circuits, offering a route to the desire/arousal component rather than penile hemodynamics.[8](https://peptidevox.com/#r8) The unifying theme: peptides target central desire/arousal; PDE5 inhibitors target peripheral blood flow — conceptually complementary, not a proven replacement.

## Which peptides actually have human evidence for ED?

Only three peptides carry any human sexual-function data, and the depth differs sharply. The table below summarizes the honest state of the evidence; the ranked list above analyzes each in detail alongside the PDE5-inhibitor reference standard.

  Peptides studied for erectile dysfunction — human evidence at a glance

    PeptideBest human evidence for EDGrade

    Bremelanotide (PT-141)Multiple Phase 2 trials incl. 2008 Phase 2b in sildenafil non-responders (33.5% vs 8.5% response); male program halted 2007–08B (male ED)
    Melanotan-2 (MT-II)Single 10-man 1998 crossover RCT (8/10 responders); but documented permanent priapism-induced EDB effect / D safety
    Kisspeptin-54One 32-man crossover RCT, IV, surrogate endpoint (tumescence to erotic video, +56% vs placebo)B
    Kisspeptin-10 (consumer form)Not tested for ED; extrapolated from kisspeptin-54 — no controlled ED dataX (unclear)
    PDE5 inhibitors (reference)AUA first-line; vast RCT base and real-world record over decadesA

Bremelanotide has the deepest dataset. Its Phase 1 intranasal trial showed a significant erectile response versus placebo at doses above 7 mg,[1](https://peptidevox.com/#r1) and the 2008 Phase 2b in sildenafil non-responders reported a clinically meaningful response in 33.5% of treated men versus 8.5% on placebo.[4](https://peptidevox.com/#r4) That is real, replicated Phase 2 human ED evidence. But there is no Phase 3 ED program and no FDA approval for ED: the FDA halted the intranasal trials in 2007 over dose-dependent blood-pressure increases, and Palatin discontinued the program in 2008, pivoting to subcutaneous dosing for female HSDD.[4](https://peptidevox.com/#r4) That female product, Vyleesi, gained FDA approval on June 21, 2019 — for desire in premenopausal women, not erections in men.[2](https://peptidevox.com/#r2)[3](https://peptidevox.com/#r3) Anyone can verify the actual approved indication directly from the [FDA Vyleesi prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf), which describes premenopausal HSDD in women and contraindicates use in uncontrolled hypertension or known cardiovascular disease.[2](https://peptidevox.com/#r2)

Melanotan-2 is PT-141's parent compound. The foundational human study is a double-blind, placebo-controlled crossover RCT in 10 men with psychogenic ED: subcutaneous MT-II at 0.025 mg/kg produced erections in 8 of 10 men, with over-80%-tip-rigidity duration of 38.0 minutes on MT-II versus 3.0 minutes on placebo (P=0.0045).[5](https://peptidevox.com/#r5) That erectogenic effect alone would grade B — but safety grades D, and safety is decisive. MT-II is sold illegally as a tanning agent, and its central melanocortin activity causes priapism. In one reported case, a 55-year-old man developed a 30-hour ischemic priapism after a single 2-mg injection and, despite aspiration, phenylephrine and operative decompression, had PDE5i-unresponsive ED at 15-week follow-up.[6](https://peptidevox.com/#r6) Other cases include melanotan-induced ischemic priapism requiring cavernosal aspiration and systemic toxicity.[7](https://peptidevox.com/#r7) The drug taken to cause erections can permanently destroy them.

Kisspeptin is the most interesting emerging signal. In a double-blind, two-way crossover RCT, 32 men with hypoactive sexual desire disorder received IV kisspeptin-54 (1 nmol/kg/h for 75 minutes) versus placebo; kisspeptin increased penile tumescence to erotic video by up to 56% (P=.02), increased happiness about sex, and modulated the brain's sexual-arousal network on fMRI — with no adverse events and no significant cardiovascular changes.[8](https://peptidevox.com/#r8) But this is single-study, surrogate-endpoint, n=32, IV-only evidence using kisspeptin-54 — not the shorter kisspeptin-10 fragment sold commercially, which has no controlled ED data.[8](https://peptidevox.com/#r8)

## What does the evidence NOT support?

Claims that fail the evidence
"PT-141 is an FDA-approved ED drug" (false — it is approved only for female HSDD); "peptides are safer than Viagra" (unsupported — PDE5 inhibitors are the AUA standard with a vast safety record, while peptides carry blood-pressure or priapism risk); "melanotan-2 is a good way to get firmer erections" (dangerously false — it has caused permanent ED); and "kisspeptin-10 injections cure ED" (unsupported — only IV kisspeptin-54 was tested, on a surrogate endpoint).[2](https://peptidevox.com/#r2)[6](https://peptidevox.com/#r6)

No peptide has out-performed PDE5 inhibitors in a head-to-head ED trial.[9](https://peptidevox.com/#r9) Just as important, these peptides do not fix the cause of ED. Erectile dysfunction is commonly a downstream marker of cardiovascular, metabolic (diabetes/insulin resistance), hormonal (low testosterone, thyroid), sleep (apnea), medication-related or psychological disease. Centrally-acting peptides mask the arousal deficit without addressing the upstream driver — and may be contraindicated precisely because of that underlying disease, since the melanocortins are contraindicated in the cardiovascular disease that often underlies ED.[2](https://peptidevox.com/#r2)[9](https://peptidevox.com/#r9)

## What is the safety and legal picture, and what should a patient actually do?

**Cardiovascular / blood pressure** is the dominant melanocortin risk: bremelanotide transiently raises blood pressure (~6/3 mmHg) and lowers heart rate, and it is contraindicated in uncontrolled hypertension and known cardiovascular disease.[2](https://peptidevox.com/#r2) Because ED is itself a sentinel marker of vascular disease, the ED population overlaps heavily with the contraindicated population. **Priapism** is the dominant melanotan-2 risk — ischemic priapism lasting up to 30 hours, requiring emergency aspiration and surgery, and resulting in permanent ED; any erection lasting more than four hours is a urologic emergency.[6](https://peptidevox.com/#r6)[7](https://peptidevox.com/#r7) Do not combine central melanocortin agents with PDE5 inhibitors or nitrates without physician supervision, as the additive vascular and pro-erectile effects raise the risk of hypotension or priapism.

**Legal status (current as of 2026):** bremelanotide is an FDA-approved prescription drug (Vyleesi) for female HSDD only, so male/ED use is off-label; compounded bremelanotide exists under Section 503A with a patient-specific prescription but is not an FDA-approved ED product.[2](https://peptidevox.com/#r2)[3](https://peptidevox.com/#r3) Melanotan-2 has no approval anywhere and is illegal to sell as a medicine.[6](https://peptidevox.com/#r6) Kisspeptin is investigational, with human sexual-arousal data confined to the research setting.[8](https://peptidevox.com/#r8) For athletes, bremelanotide is not listed by name on the 2026 WADA Prohibited List, but kisspeptin's effects on endogenous hormones may fall under broad hormone-modulator catch-all categories; tested athletes must verify against the primary WADA list.[10](https://peptidevox.com/#r10)

**Bottom line.** From a functional, root-cause view, ED is most often a message, not a disease. The highest-value, best-evidenced actions are a real medical workup (cardiovascular, glycemic, lipid, testosterone, thyroid, sleep, medication review), correcting upstream drivers (weight/insulin sensitivity, sleep apnea, sedentary lifestyle, smoking, excess alcohol, offending medications, psychological factors), and — when pharmacotherapy is appropriate — first-line PDE5 inhibitors under medical supervision.[9](https://peptidevox.com/#r9) The strongest peptide candidate for the mechanism of ED is the melanocortin pathway, and kisspeptin is the most interesting emerging signal — but for an actual patient with ED in 2026, the evidence-based answer is not a peptide.

---
Source: https://peptidevox.com/sexual-hormonal-health/peptides-for-erectile-dysfunction
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt